J&J highlights FGFR inhibitor data ahead of ASCO

Johnson & Johnson (NYSE:JNJ) unveiled for the first time data for its fibroblast growth factor receptor (FGFR) inhibitor, erdafitinib (JNJ-42756493). In the Phase II BLC2001 trial, erdafitinib led to a confirmed objective response rate (ORR) of 70% in 21 evaluable urothelial carcinoma patients who received prior immune checkpoint inhibitors.

The data were released late Wednesday in an abstract ahead of the American Society of Clinical Oncology meeting in Chicago...